文献速递中医内科中药与中成药合理使用

溃疡性结肠炎中微生物群-宿主交互与中药转化前景

Microbiota-host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine.
PubMed 文献 · Front Pharmacol · 2026-10-09

本文综述溃疡性结肠炎中微生物群-代谢-屏障-免疫网络,并评估中医药对其影响。人类多组学显示菌群失调在功能和代谢物层面比个别菌群更可重复。中药证据多来自实验性结肠炎,人类干预证据有限,需标准化产品与因果验证。

要点

  • 菌群功能与代谢物改变比菌群相对丰度更稳定。
  • 中药调节菌群证据多来自动物与细胞实验。
  • 现有临床试验短期有效但受制剂与剂量影响。

核心结论

  • 中医药调节菌群的临床疗效尚未确立,需标准化产品与因果实验验证。

研究设计与样本

  • 叙述性综述,分析微生物群-代谢-屏障-免疫网络及中医药干预证据。

主要发现

  • 人类多组学显示菌群失调在功能和代谢物层面比个别菌群更可重复。
  • 短链脂肪酸、胆汁酸、色氨酸衍生物吲哚、精氨酸和胆碱相关代谢物参与上皮与免疫调节。
  • 中药调节菌群证据多来自化学诱导实验性结肠炎、类器官或细胞系统。
  • 靛玉红、姜黄素-青黛、穿心莲提取物、姜黄素及部分中药复方试验提供短期疗效信号,但结果依赖制剂与剂量。

临床怎么用

  • 现有证据不足以将属水平相对丰度变化视为微生物获益或介导的证明。
  • 临床转化需化学标准化产品、严格安全监测及菌株与功能解析的微生物组检测。
  • 需设计实验区分中药直接作用与微生物依赖效应,并整合内镜、组织学、药代、微生物、代谢及长期安全性结局。

局限性

  • 人类干预证据有限,多数机制证据来自实验性结肠炎、类器官或细胞系统。
  • 现有临床试验结果受制剂和剂量影响,尚未确立微生物介导的临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ulcerative colitis (UC) is sustained by reciprocal interactions among intestinal dysbiosis, altered microbial metabolism, epithelial barrier dysfunction, and mucosal immune activation. This narrative review examines that microbiota-metabolism-barrier-immune network and evaluates how traditional Chinese medicine (TCM) may influence it. Human multi-omics studies indicate that UC-associated dysbiosis is more reproducible at the level of microbial function and metabolite output than at the level of individual taxa. Experimental studies further implicate short-chain fatty acids, bile acids, tryptophan-derived indoles, arginine, and choline-related metabolites in epithelial and immune regulation. Most evidence for TCM-mediated microbiota modulation, however, comes from chemically induced experimental colitis, organoid, or cell systems; human interventional evidence remains limited. We therefore grade mechanistic evidence from association through microbiota dependence, candidate strain/metabolite sufficiency, host-target validation, and integrated causal-chain validation. This distinction avoids treating genus-level relative-abundance changes as proof of microbial benefit or mediation. Emerging clinical trials of indigo naturalis, Curcumin-QingDai, Andrographis paniculata extract, curcumin, and selected multicomponent Chinese herbal therapies provide short-term efficacy signals, but results are preparation- and dose-dependent and do not yet establish microbiota-mediated clinical efficacy. Translation will require chemically standardized products, rigorous safety surveillance, strain- and function-resolved microbiome measurements, explicit experiments separating direct herbal actions from microbiota-dependent effects, and clinical trials incorporating endoscopic, histological, pharmacokinetic, microbial, metabolic, and long-term safety outcomes.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen J, Du J, Mu B, et al. Microbiota-host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine. Front Pharmacol. 2026. PMID: 42920884. doi:10.3389/fphar.2026.1956353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。